Knowledge Library
Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond
Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery
Establishment of spatial transcriptomics assay to find the mechanism of immune therapy against tumors
Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
Evaluation of the efficacy of ADC in vitro and in vivo
Abstract Antibody drug conjugate (ADC) is a promising complex with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, ADCs-derived monoclonal antibody is conjugated with cytotoxic agents which can deliver potent cellular toxins to targeted cancer cells specifically. According to the specialization of ADCs, we …Read More >